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Recent studies demonstrated an association between the K153R polymorphism in the myostatin
gene with extreme longevity, lower muscle strength and obesity but the molecular basis of these
associations has not been clarified. Here, we show that the K153R mutation significantly increases
the rate of proteolysis of promyostatin by furin, but has no effect on the activity of the latent com-
plex or the cleavage of the latent complex by bone morphogenetic protein 1 (BMP-1). The increased
rate of activation of K153R mutant promyostatin may explain why this polymorphism is associated
with obesity, lower muscle strength and extension of lifespan.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical
Societies. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction interfere with the formation of mature myostatin were also shownMyostatin, similarly to other members of the TGF-b family, is
secreted as a precursor protein, promyostatin [1]. Two molecules
of promyostatin are covalently linked via a single disulfide bond
present in the C-terminal growth factor domain. Mature myostatin
is liberated from promyostatin by proteolytic processing. In the
first step of myostatin activation furin type proprotein convertases
cleave both chains of the homodimeric precursor at the boundary
of the prodomain and the growth factor domain. The two prodo-
mains and the disulfide-bonded growth factor domains remain
associated, forming a non-covalent complex [2], usually referred
to as a latent complex. Mature growth factor is liberated from this
latent complex through degradation of the prodomain by proteases
of the BMP-1/Tolloid family of metalloproteinases [3].
Myostatin is a negative regulator of skeletal muscle growth:
mice lacking myostatin are characterized by a dramatic increase
in skeletal muscle mass [4]. Mutations in the myostatin gene thatto cause hypermuscularity in mice and cattle [5–8]. A mutation in
the myostatin gene leading to mis-splicing and loss of myostatin
protein was shown to cause muscle hypertrophy in a human child
[9].
Myostatin is also involved in regulation of adipose tissue: in
Mstn-/- mice adipose tissue size is greatly reduced [10–11]. The
positive effects of myostatin inhibition on adipose tissue seem to
be indirect results of the changes of muscle mass and muscle
metabolism [12].
Human genomic studies have identified several missense sub-
stitutions in the coding region of the human myostatin gene affect-
ing conserved amino acid residues: A55T, K153R, E164K, P198A,
and I225T [13]. Two of these, A55T and K153R, were shown to be
polymorphic in the general population [13].
Several recent studies suggest that the most common polymor-
phism K153R may have significant functional consequences. Saun-
ders et al. [14] provided compelling evidence that mutation K153R
has been subject to recent positive selection, suggesting that it is
associated with functional differences.
Recent studies indicate that the K153R mutation may have
three major types of phenotypic consequences: on muscle, on adi-
pose tissue and on lifespan.
In a cohort of older women significant association was found
with the maintenance of muscle strength and the K153R polymor-
phism: the R153 allele was associated with lower muscle strength
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had no negative influence on the muscle phenotypes of women,
but the woman bearing the RR genotype had very low values of
muscle mass and functional capacity [16]. In a study with non ath-
letic young men, Santiago et al. [17] found that the K153R poly-
morphism affects the ability to produce ‘peak’ power during
muscle contractions: men with the KR genotype had a worse per-
formance in vertical jumps compared with those with the wild-
type KK genotype [17].
The K153R variant of myostatin was found to predispose to
obesity in Asian Indians: the RR genotype of the K153R polymor-
phism was found to be associated with a high risk of obesity [18].
The K153R polymorphism was also shown to be associated with
longevity [19]: in a Spanish cohort of centenarians the study of the
genotype distributions of the exonic myostatin variants showed
that the frequency of the R allele of the K153R polymorphism
was significantly higher in centenarians (7.1%) than in controls
(2.7%). These results were independently confirmed in an Italian
study, where a higher frequency of the R allele was found in cente-
narians (7.6%) compared to controls (3.0%), indicating that the var-
iant allele of the myostatin K153R polymorphism could be among
the genetic contributors associated with exceptional longevity.
These authors suggested that the beneficial effect of the K153R
mutation on longevity is based on the inhibitory role that myosta-
tin plays in the mTOR signaling pathway.
In summary, the most common polymorphism of the human
myostatin gene, the K153R polymorphism, shows significant asso-
ciation with lower muscle strength and obesity. Since this is just
the opposite of what we observe in the case of mutations leading
to loss of myostatin activity, it seemed plausible to assume that
the K153R mutation might increase myostatin activity. To address
this question, in the present work we have studied the molecular
properties of recombinant myostatin precursor carrying the
K153R mutation and compared its properties with those of the
wild-type protein. Our studies have shown that the K153R substi-
tution significantly increases the rate of furin cleavage but has no
effect on the activity of latent myostatin or its cleavage by BMP-
1. Since latent myostatin is known to have significant activity
[20], an increase in the amount of furin-activated myostatin and
concomitant increase in myostatin activity may explain the
observed association of K153R mutation with lower muscle
strength and obesity.
We suggest that the association of the K153R mutation with
extreme longevity is also explained by increased myostatin activ-
ity. It is noteworthy in this respect that the myostatin ortholog of
Drosophila, myoglianin, has been recently shown to control longev-
ity: its overexpression in muscle extends lifespan and delays sys-
temic aging of flies by acting on muscle and adipocytes [21],
raising the possibility that myostatin may also regulate lifespan
in mammals [22].
2. Materials and methods
2.1. Reagents, enzymes, PCR primers, proteins, bacterial strains, cell
lines, and media
Mutagenesis primers were from Integrated DNA Technologies
(Coralville, IA, USA). The mutagenesis reaction was performed with
Quickchange mutagenesis kit (Agilent Technologies, Inc. Santa
Clara, CA USA). DNA was purified with Nucleospin Extract DNA
purification kit (Macherey–Nagel, Duren, Germany). Escherichia coli
JM109 was used for DNA propagation during DNA manipulation
steps, and E. coli BL21(DE3) strain was used for protein expression.
For the Luciferase reporter assay the SBE4 SMAD responsive fire-
fly luciferase plasmid was from Addgene (Addgene plasmid 16495;
www.addgene.org, Cambridge, MA, USA). RhabdomyosarcomaA204 and HEK 293 cells were purchased from German Collection
of Microorganisms and Cell Cultures (DSMZ, Braunschweig,
Germany); Fugene HD transfection reagent was from Promega
(Promega Corporation, Madison, WI, USA). DMEM and McCoy’s 5A
culturemedium and heat-inactivated fetal bovine serumwere from
Invitrogen (Carlsbad, CA, USA).
Recombinant human promyostatin was produced in E. coli as
described previously [20]. Recombinant furin, recombinant BMP-
1, anti-Mouse Myostatin Propeptide sheep polyclonal antibody
(AF1539) (R&D Systems, Minneapolis, MN, USA), alkaline phospha-
tase conjugated anti-sheep antibody (Sigma–Aldrich, St Louis, MO,
USA) and Furin Inhibitor I (Merck Millipore, Darmstadt, Germany)
were commercial products. Mammalian expression vectors of the
Stargate system, pENTRY-IBA51 and pCSG-IBA142, were purchased
from IBA BioTAGnology (Göttingen, Germany).
2.2. Production of the K153R mutant human promyostatin in
Escherichia coli
Mutagenesis was performed with QuikChange Site-Directed
Mutagenesis, using the 50 CAA TAC AAT AAA GTA GTA AGG GCC
CAA CTA TGG ATA TAT 30 sense and 50 ATA TAT CCA TAG TTG
GGC CCT TAC TAC TTT ATT GTA TTG 30antisense primers. The
expression plasmid pPR-IBA2_Promyo containing the cDNA of
human promyostatin [20] was the template in the mutagenesis
reaction. The mutagenesis introduced an A to G change at position
458 of the human promyostatin cDNA causing the K153R mutation
in the protein. E. coli BL21(DE3) cells were transformed with the
pPR-IBA2_Promyo_K153R plasmid and protein expression, refold-
ing and purification was performed with the same method that
was used for the production of the recombinant wild type human
promyostatin [20].
2.3. Proteolytic digestion of wild type and K153R mutant promyostatin
with human furin
To monitor furin-mediated cleavage of wild type and K153R
mutant promyostatins by SDS–PAGE, the recombinant proteins
(1–1 lM) were digested with human furin (1 lg/ml) in 100 mM
Tris–HCl, 150 mM NaCl, 1 mM CaCl2, 100 lM PMSF buffer, pH 8.0
at 28 C. Aliquots were removed at various time points (0 h, 1 h,
4 h, 24 h) and the composition of the samples was analyzed by
SDS–PAGE.
Wild type and K153R mutant latent myostatins were produced
by digesting the protein samples (1 lM) with 3.5 lg/ml furin in
100 mM Tris–HCl, 150 mM NaCl, 1 mM CaCl2, 100 lM PMSF buffer,
pH 8.0 at 28 C for 24 h. The digestion was arrested with 1 lM
Furin Inhibitor I; samples were stored at 20 C.
2.4. Proteolytic digestion of wild type and K153R mutant latent
myostatin with human BMP-1
To monitor BMP-1 cleavage of wild type and K153R mutant
latent myostatin by SDS–PAGE, latent myostatin preparations
(1 lM) were digested with 2.5 lg/ml BMP-1 in 25 mM HEPES buf-
fer, pH 7.5 containing 5 mM CaCl2, 1 lM ZnCl2 and 1 lM Furin
Inhibitor I at 37 C. Aliquots were removed at various time points
(0 h, 1 h, 4 h, 24 h) and the composition of the samples was ana-
lyzed by SDS–PAGE.
2.5. Expression of wild type and K153R mutant promyostatin in HEK
293 human embryonic kidney cells
The cDNA of promyostatin was first cloned into the pENTRY-
IBA51 entry vector, then transferred to the pCSG-IBA142
mammalian expression vector according to the instructions of
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was used as the template of the Quickchange mutagenesis
reaction; mutagenesis was performed with the primers given in
Section 2.2.
HEK 293 cells were transfected with 3 lg of either pCSG-
IBA142-Promyo, pCSG-IBA142-PromyoK153R or pCSG-IBA142-
control plasmids with Fugene HD transfection reagent according
to the recommendations of the manufacturer. 24 h after transfec-
tion the culture media were changed to serum-free DMEM and
transient protein expression was allowed for 48 h. The media were
concentrated 25-fold and the expressed recombinant proteins
were visualized on Western blots using antibody AF1539, specific
for the prodomain region of myostatin.
2.6. Protein analyses
The concentrations of the recombinant promyostatin proteins
were calculated with the extinction coefficient 55640 M1 cm1.
The extinction coefficient was calculated with the online protein
analysis tool PROTPARAM. (http://web.expasy.org/protparam/).
The composition of protein samples was analyzed by SDS–PAGE
under both reducing and non-reducing conditions; unless other-
wise indicated, the gels were stained with Coomassie Brilliant Blue
G-250. For quantitative evaluation of protein compositions the gels
were stained with SYPRO Ruby (Bio-Rad Laboratories Hercules CA
USA), the stained gels were scanned with the ChemiImager 5500
gel documentation instrument (Alpha Innotech, San Leandro, CA,
USA) and the intensities of the protein bands were quantified with
the instrument’s software.
To compare the rates of furin-mediated cleavage of wild type
and K153R mutant promyostatin we monitored the proportion of
uncleaved promyostatin chains. The rates of BMP-1 cleavage of
wild type and K153R mutant latent myostatins were compared
in a similar way except that in this case we monitored the propor-
tion of uncleaved prodomain chains. Statistical analyses of the data
were performed with Student’s t-test.
2.7. Reporter assay
Rhabdomyosarcoma A204 cells were cultured in McCoy’s 5A
medium supplemented with 10% fetal bovine serum, penicillin
(100 U/mL) and streptomycin (100 lg/mL) at 37 C, 5% CO2.
3  104 cells were plated in wells of a 96-well plate and were
allowed to attach for 24 h. The cells were transiently transfected
with 200 ng Luciferase Reporter vector mixture and 0.6 ll Fugene
HD reagent per well. Luciferase Reporter vector mixture contained
the SBE4 SMAD responsive firefly luciferase plasmid (Addgene
plasmid 16495) and a constitutive Renilla luciferase plasmid in
40:1 ratio [23].
Transfections were performed in McCoy’s 5A medium contain-
ing 10% FBS without antibiotics. 24 h later, the transfection med-
ium was changed to McCoy’s 5A containing 1 mg/ml BSA and
conditioned for 18 h. McCoy’s 5A medium containing 1 mg/ml
BSA and different concentrations of recombinant proteins were
added to the cells and after 6 h, the cells were washed twice with
PBS and lysed using 50 ll passive lysis buffer (Promega Corpora-
tion). Firefly and Renilla luciferase activities were measured on
an Enspire Multimode Reader (PerkinElmer, Waltham, MA USA).
The firefly luciferase units obtained were normalized to the Renilla
luciferase units to generate relative luciferase units. Statistical
analyses of the data were performed with Student’s t-test.
2.8. Protein modeling
The homology model of promyostatin was generated with
the automated protein structure homology-modeling serverSWISS-MODEL Version 8.05 (http://swissmodel.expasy.org/; [24–
25]. The template was identified from the SWISS-MODEL template
library (SMTL version 2014-07-09, PDB release 2014-07-03) with
the automated template search of the pipeline. The model was
based on the selected 3rjr.1.A file that contains the structure of
porcine proTGFbeta1 [26]. The sequence identity between human
myostatin and porcine proTGFbeta1 was 31.68% over the aligned
region (residues 49–375 of promyostatin). The model generated
by the pipeline was analyzed with Swiss-PdbViewer DeepView
version 4.01 (http://spdbv.vital-it.ch/; [27]). For further details of
homology modeling of human promyostatin see Supplementary
file 1.3. Results
3.1. The K153R mutation does not impair the folding of promyostatin
K153R promyostatin was expressed in E. coli cells and refolded
from inclusion bodies according to the protocol described previ-
ously [20]. The yields and efficiency of refolding of the mutant
protein were indistinguishable from that of the wild type prom-
yostatin, indicating that the replacement of a lysine residue by
an arginine at position 153 had no deleterious effect on the struc-
ture of promyostatin. This conclusion is also supported by the
observation that mutant promyostatin may be activated by furin
and BMP-1 to yield mature myostatin (see below). Similarly, our
observation that human HEK 293 cells transfected with K153R
mutant promyostatin secreted the precursor as efficiently as the
wild type protein (see Supplementary file 2) indicates that the
mutation has no deleterious effect on the folding and secretion of
the protein.
3.2. The K153R mutation in promyostatin significantly enhances the
rate of cleavage by furin
Wild type and K153R mutant promyostatin were digested with
furin and samples were withdrawn after 0 h, 1 h, 4 h and 24 h of
digestion and their composition was analyzed by SDS PAGE under
both reducing and non-reducing conditions as described in Section
2. As shown in Fig. 1A, furin-digestion of both mutant and wild-
type promyostatin proceeds through an intermediate (semipro-
myostatin) in which only one of the chains of promyostatin dimer
is cleaved by furin (non-reduced samples).
The mutant protein, however, is cleaved by furin at a
significantly higher rate than the wild type promyostatin.
Quantitative evaluation of the gels has shown that the propor-
tion of uncleaved promyostatin decreased at a significantly
higher rate in the case of the K153R mutant protein than in
the case of the wild type protein (Fig. 1B). Note that at 4 h
and 24 h the proportion of the uncleaved K153R mutant prom-
yostatin is significantly (⁄P < 0.05) lower than in the case of wild
type promyostatin.
3.3. The K153R mutation does not influence the rate of cleavage of
latent myostatin by BMP-1
Wild type and K153R mutant latent myostatins were digested
with BMP-1 for 0 h, 1 h, 4 h and 24 h and the samples were ana-
lyzed by SDS–PAGE as described in Section 2 (Fig. 2A). Quantitative
evaluation of the gels has shown that the proportion of uncleaved
myostatin prodomain decreased at a similar rate in the case of both
the wild type and K153R mutant protein (Fig. 2B). Statistical anal-
ysis of the data revealed that the proportion of the uncleaved
myostatin prodomain is not significantly different in the case of
wild type and mutant myostatin at any of the time points. This
Fig. 1. Cleavage of recombinant wild type and K153R mutant human promyostatin by furin. Promyostatins (1000–1000 nM) were incubated with recombinant human furin
(1 lg/ml) in 100 mM TRIS–HCl, 150 mM NaCl, 1 mM CaCl2, 100 mM phenylmethanesulphonyl fluoride buffer, pH 8.0 at 28 C for 1 h, 4 h and 24 h. Panel A: monitoring furin–
mediated cleavage of promyostatin by SDS–PAGE analysis. The left side of the panel shows non-reduced samples, the right side of the panel shows samples reduced by b-
mercaptoethanol (+b-ME); the gels were stained with Coomassie Brilliant Blue G-250. Note that in the case of non-reduced samples there is an intermediate
(semipromyostatin) in which only one of the chains of promyostatin dimer is cleaved by furin. Also note that on non-reduced gels dimeric myostatin appears as a diffuse
faintly stained band. Panel B: K153R mutant human promyostatin is cleaved by furin at a significantly higher rate than wild type promyostatin. Furin–mediated cleavage of
promyostatin was monitored by SDS–PAGE analysis as in panel A and the proportion of uncleaved promyostatin was determined under reducing conditions following
staining with SYPRO Ruby. The stained gels were scanned with a ChemiImager 5500 gel documentation instrument and the intensities of the protein bands were quantified
with the instrument’s software. Furin digestion was followed by monitoring the decrease in the proportion of uncleaved wild type and K153R mutant promyostatin. The bars
represent the average of six measurements. Note that at 4 h and 24 h the proportion of the uncleaved K153R mutant promyostatin (white bars) is significantly (⁄P < 0.05)
lower than in the case of wild type promyostatin (black bars).
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effect on BMP-1 cleavage of myostatin prodomain.
3.4. The K153R mutation does not influence the activity of latent
myostatin
To test whether the K153R mutation has an influence on the
activity of the various forms of promyostatin we have monitored
myostatin activity in reporter assays as described in Section 2.
As shown in Fig. 3, both wild type and K153R mutant promyost-
atin were devoid of activity: the Relative Luminescence
Units were not significantly higher than in the case of control
medium.
In harmony with our previous observations [20] wild type
latent myostatin had low, but significantly higher (⁄P < 0.05) activ-
ity than wild type promyostatin. In this respect, the K153R mutant
was similar to wild type: it also had low, but significantly higher
(⁄⁄P < 0.01) activity than mutant promyostatin. The fact that
BMP-1 cleavage of both wild type and K153R mutant latent myo-
statin elicited a similar and significant (⁄⁄⁄P < 0.001) increase in
myostatin activity is consistent with the observation that the
mutant and wild type proteins are equally sensitive to BMP-1
cleavage (see Section 3.3.).4. Discussion
4.1. Effect of the K153R mutation on the structure of human
promyostatin
In the present work we have shown that the K153R substitution
(present in the prodomain region of promyostatin) significantly
increases the rate of cleavage by furin, but has no effect on the
activity of latent myostatin or on the rate of its cleavage by BMP-
1. The most plausible explanation for such a specific effect on
furin-cleavage is that the substitution of the Lys-153 residue by
an arginine residue does not cause a gross alteration in the overall
structure of promyostatin, but might cause more subtle changes
that affect furin-cleavage.
Although, the three-dimensional structure of promyostatin is
unknown, its homology with pro-TGF-b1 permitted the construc-
tion of a homology model based on the known crystal structure
of the latter protein [26]. Based on sequence alignments Shi et al.
[26] have suggested that prodomains of TGF-b family members
have similar folds. Of particular interest is the fact that myostatin
is a relatively close homolog of TGF-b1, permitting the assumption
that the secondary structural elements and their spatial arrange-
ment are similar in these proteins [26].
Fig. 2. Cleavage of latent human K153R myostatin by BMP-1. Latent wild type and latent K153R mutant human myostatins (1000–1000 nM) were digested with 2.5 lg/ml
BMP-1 in 25 mM HEPES buffer, pH 7.5 containing 5 mM CaCl2, 1 mM ZnCl2 and 1 mM Furin Inhibitor I at 37 C for 1 h, 4 h and 24 h. Panel A: monitoring BMP-1 cleavage of
latent myostatins by SDS–PAGE analysis. The left side of the panel shows non-reduced samples, the right side of the panel shows samples reduced by b-mercaptoethanol (+b-
ME); the gels were stained with Coomassie Brilliant Blue G-250. Panel B: latent wild type and latent K153R mutant human myostatins are cleaved by furin at a similar rate by
BMP-1. BMP-1 cleavage of latent myostatins was monitored by SDS–PAGE analysis as in panel A and the proportion of uncleaved prodomain was determined following
staining with SYPRO Ruby. The stained gels were scanned with a ChemiImager 5500 gel documentation instrument and the intensities of the protein bands were quantified
with the instrument’s software. The degree of BMP-1 cleavage of wild type and the K153R mutant prodomains was assessed from the decrease of the proportion of uncleaved
prodomain. The bars represent the average of six measurements. Note that the proportion of the uncleaved mutant myostatin prodomain (white bars) is not significantly
different in the case of wild type and mutant myostatin (black bars) at any of the time points.
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of myostatin, Fig. 4), the N-terminal part of the prodomain
provides the ‘straitjacket’ that interacts with the growth-factor
monomer. The ‘straitjacket’ consists of the a1 helix and the
‘latency lasso’, the coiled linker region that connects the a1 and
a2 helices of the prodomain. Our observation that substitution of
Lys-153 by an arginine does not affect the activity of latent myost-
atin is consistent with the fact that Lys-153 is relatively distant
from the a1 helix-growth factor interaction (Fig. 4). Similarly, the
observation that substitution of Lys-153 by an arginine does not
affect BMP-1 cleavage of latent myostatin is in harmony with the
fact that Lys-153 is remote from the BMP-1 cleavage site (Fig. 4).
In the crystal structure of pro-TGF-b1 no coordinates were
recorded for the long, flexible prodomain–growth-factor connection
(http://www.rcsb.org/pdb/explore.do?structureId=3RJR), therefore
the structure of this linker in the homology model is uncertain.
Nevertheless, we note with interest that this flexible linker region,
that contains the RXRR furin recognition motif (Arg263-Ser264-
Arg265-Arg266), is relatively close to Lys-153 (Fig. 4), suggesting
that replacement of Lys-153 by an arginine residue may increase
the accessibility of the cleavage site for furin. However, it is also
possible that the effect of the K153? R153 substitution on furin-
cleavage reflects the known affinity of furin for polyarginines
[27]. Studies on the crystal structures of furin [28–30] revealed
that the targeting of substrates is dominated by extended electro-static interactions with 18 clustered negatively charged residues in
the substrate binding cleft of the enzyme and that this extended
site may bind arginines not only at the at the S1, S2 and S3 sites,
but also at the S5 and S6 subsites. It seems possible that in the case
of the K153R mutant of promyostatin the side chain of Arg-153
may also contribute to the recognition of the cleavage-site by furin,
and this could explain why this mutant is more susceptible to furin
cleavage.
4.2. Effect of the K153R mutation on human phenotype
Since the K153R mutation makes promyostatin more suscepti-
ble to furin-cleavage, the mutation may facilitate the formation
of latent myostatin in individuals carrying this mutation. We have
shown that both wild type [19] and K153R mutant (present study)
latent myostatin have significant activity, therefore elevation in
the levels of latent myostatin results in myostatin activity even
in the absence of BMP-1 cleavage. On the basis of these consider-
ations it is plausible to assume that individuals carrying the
K153R mutation may have higher myostatin activity than individ-
uals with the wild type genotype. Since myostatin is a negative
regulator of muscle mass [4] and a positive regulator of adipose tis-
sues [10,11] increased myostatin activity may provide an explana-
tion as to why the K153R polymorphism is associated with lower
muscle strength and obesity.
Fig. 3. Luciferase reporter assay of myostatin activity of wild type and K153R
mutant human promyostatin and their derivatives. Rhabdomyosarcoma A204 cells
were transiently transfected with the SMAD Luciferase reporter vector and a Renilla
luciferase vector, and incubated for 16 h with different forms of myostatin (5 nM).
Firefly luciferase units were normalized to Renilla luciferase units. The activities of
promyostatins and their derivatives are expressed in Relative luminescence units,
relative to the luminescence observed with the control medium. PM: promyostatin;
LM: latent myostatin; LM-BMP1: latent myostatin digested with BMP-1. The bars
represent the average of six parallel experiments with the wild type (black bars)
and K153R mutant proteins (white bars). Note that both wild type and mutant
latent myostatin have significantly higher activity than the corresponding prom-
yostatins even in the absence of BMP-1 cleavage. Values are means ± standard
errors. ⁄P < 0.05 versus control samples; ⁄⁄P < 0.01 versus control samples
⁄⁄⁄P < 0.001 versus control samples.
Fig. 4. Protein modeling of the 3D structure of human promyostatin. The figure
shows the model of human promyostatin highlighting the position of the residues
adjacent to the BMP-1 cleavage site (residues Arg-98/Asp-99), the furin-cleavage
site (Arg263-Ser264-Arg265-Arg266/Asp267) and the position of Lys-153 that is
replaced by an Arg in the K153R mutant myostatin. The growth factor domain of
promyostatin is shown in gold. The homology model was computed using the
structure of pro-TGF-b1 as a template.
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with extreme longevity is less clear but the most parsimonious
explanation is that it is also due to increased myostatin activity.
It is noteworthy in this respect that recent studies have directly
implicated the fly ortholog of myostatin, myoglianin, in controlling
lifespan [21,22]. These authors have shown that myoglianin over-
expression in flies extends lifespan, whereas myoglianin RNAi
has converse effects, leading them to suggest that myostatin
may have a similar role in regulating lifespan in mammals. Theassociation of the K153R mutation (and its increased myostatin
activity) with extreme longevity in humans is in harmony with this
hypothesis.
Garatachea et al. [19] suggested that the beneficial effect of the
R allele on exceptional longevity is based on the inhibitory role that
myostatin plays in the mTOR signaling pathway. The strongest
argument in favor of this interpretation is that the most robust
improvements in ageing are caused by dietary restriction and
genetic down-regulation of nutrient-sensing pathways, such as
the mTOR pathway [31,32]. However, it is also possible that asso-
ciation of the K153R mutation of promyostatin with longevity is
less direct: myostatin might exert its effect through its influence
on skeletal muscle that in turn controls systemic aging and lifespan
[33].
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